Theravance, Inc. (NASDAQ: THRX) announced today that results with the investigational antibiotic telavancin (TD-6424), from a Phase 2 clinical study in patients with complicated Gram-positive skin and skin structure infections and from a Phase 1 study in healthy volunteers, were recently presented at the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C.
